Supernus Pharmaceuticals Inc
F:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
D
|
Dexcom Inc
F:DC4
|
US |
|
D
|
Dolby Laboratories Inc
XMUN:FUO
|
US |
|
V
|
VGI PCL
SET:VGI
|
TH |
|
Lagardere SA
F:LAG
|
FR |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
SWB:AIL
|
FR |
|
C
|
Censof Holdings Bhd
KLSE:CENSOF
|
MY |
|
C
|
Crown Holdings Inc
F:CWN
|
US |
|
D
|
Dolby Laboratories Inc
XBER:FUO
|
US |
|
C
|
Chargeurs SA
F:GET
|
FR |
|
OFS Capital Corp
NASDAQ:OFS
|
US |
|
Ascencio SCA
F:ZYY
|
BE |
Shareholder Yield
Current shareholder yield for 
S49 is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
S49 Price
Supernus Pharmaceuticals Inc
| Average Annual Return | 14.49% |
| Standard Deviation of Annual Returns | 25.47% |
| Max Drawdown | -24% |
| Market Capitalization | 2.8B EUR |
| Shares Outstanding | 54 974 300 |
| Percentage of Shares Shorted |
N/A
|
